Emerging treatments

Transcatheter tricuspid valve intervention (TTVI)

TTVI have been studied in trials and currently the European guidelines recommend that TTVI may be considered at experienced centers for symptomatic, inoperable, anatomically eligible patients in whom symptomatic or prognostic improvement can be expected.[2]​ In the TRILUMINATE trial, tricuspid transcatheter edge-to-edge repair (TEER) was compared with medical therapy in patients with symptomatic severe TR and was associated with improvements in quality of life.[35][36]​​​​ Mortality rates and hospitalizations for heart failure were similar between groups.[35]​ The TRISCEND study evaluated transfemoral tricuspid valve replacement in patients with moderate symptomatic TR despite medical therapy and found it was associated with reduced TR, and improved clinical, functional, and quality of life measures at one year of follow-up.[37][38]

Use of this content is subject to our disclaimer